about
Comparison between the analgesic and therapeutic effects of a musically modulated electromagnetic field (TAMMEF) and those of a 100 Hz electromagnetic field: blind experiment on patients suffering from cervical spondylosis or shoulder periarthritis.[The new magnetic therapy TAMMEF in the treatment of simple shoulder pain]Alterations in adenylate kinase activity in human PBMCs after in vitro exposure to electromagnetic field: comparison between extremely low frequency electromagnetic field (ELF) and therapeutic application of a musically modulated electromagnetic fieIn vitro exposure of human osteoarthritic chondrocytes to ELF fields and new therapeutic application of musically modulated electromagnetic fields: biological evidence.Human osteoarthritic chondrocytes exposed to extremely low-frequency electromagnetic fields (ELF) and therapeutic application of musically modulated electromagnetic fields (TAMMEF) systems: a comparative study.Proteomics of human primary osteoarthritic chondrocytes exposed to extremely low-frequency electromagnetic fields (ELF EMFs) and to therapeutic application of musically modulated electromagnetic fields (TAMMEF).Immune and autoimmune disorders in HCV chronic liver disease: personal experience and commentary on literature.H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease.The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questionsPrevalence of Paget's disease of bone in Italy.Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine.Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled StudyThe efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial.The prevention of fragility fractures in diabetic patients.Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients.Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure.Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.Mild brachydactyly type A1 maps to chromosome 2q35-q36 and is caused by a novel IHH mutation in a three generation family.A problematic case of chlamydia pericarditis and sicca syndrome.An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.[Evaluation of early biomarkers of cartilage degeneration in the diagnosis and clinico-therapeutic monitoring of primary osteoarthrosis]Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide.Hyperuricemia and gout in thyroid endocrine disorders.Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities.[In vitro study on the possible inflammatory mechanism of ferrous ions: effect on the production of oxygen free radicals][Erythema nodosum in Giardia lamblia infestation][Chronic liver disease in rheumatoid arthritis: complication or association?]Collagen-gelatin-genipin-hydroxyapatite composite scaffolds colonized by human primary osteoblasts are suitable for bone tissue engineering applications: in vitro evidences.Possible pathogenetic role of antiphospholipid antibodies in a clinical case of human immunodeficiency virus infection with peripheral polyneuropathy and arterial thrombosis.[Preliminary results of the effects of electromagnetic fields ELF and TAMMEF on human lymphocytes: evaluation of some biological parameters]Validation of an Italian version of the functional index for hand osteoarthritis (FIHOA).A double-blind, interpatient comparison of plain and slow-release ketoprofen in osteoarthritis.A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritis.Alpha lipoic acid and superoxide dismutase in the treatment of chronic low back pain.Haptoglobin phenotypes in systemic sclerosis.Serum relaxin in systemic sclerosis.[Usefulness of online bibliographic research in biomedical research, with an application to the epidemiologic study of genetic osteopathy]Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
P50
Q30540224-C676CD71-E674-4F1F-B0F3-AA4B470014B7Q30543380-848BCA6E-7022-42AA-BA38-FB03405DEE24Q30545778-786A2BDE-EFDB-4D3F-A09D-8C43D4329D70Q30557545-FEA2CD13-15D9-42FF-8CD3-4EF9E44E7A16Q30558532-CACE3AAE-F042-4E48-AD98-589AB7280E00Q30559161-DAC0A151-87C0-4514-BBC0-D893E03C62DBQ33369742-F745BBCE-AFF9-4FB5-918B-A78154F10CD9Q33866718-E57ADC4A-11A9-4C03-9A45-D12C80357A78Q34065957-6896A079-967F-4BE6-B386-38C17239E75BQ34450713-EF788DAE-B178-46A7-A13B-FDE50D6F75A9Q34553353-5A01C10E-A854-4911-A730-60D95B1FD445Q36278238-576CF9C9-3693-4B02-B5DF-5CF13ABA13B6Q37667284-42BC77BE-A24D-4F66-89B5-E358B75A90EAQ38233593-F753F32F-B9B4-433F-A3FD-69C4C2DA8F55Q38580674-32CDDDB6-1C7D-4B2E-AFB3-C059B3FD20AEQ39966988-5A2D1E69-D831-4400-BAEE-9324C1310483Q40820141-8666E971-9CB5-4AEA-9070-D992E4BCEDABQ42558705-93B2BD84-B58C-4D25-9C44-6F8269F03210Q43074311-60B65497-C394-4ACC-9EC8-C4116A30F00DQ43431947-F0F350B2-6637-4A99-BC44-82A8C76CF0E6Q43435239-6EA5F0A0-8182-4615-8592-4C597658758CQ43695722-BFF89B3E-6CA1-4B0C-8C21-856D5983A0FEQ43787856-D8A1F9C8-602A-4B5A-8070-352093D334CAQ43852885-CE0A26A0-E23C-4737-90BC-A39CA074E917Q43854809-14B1CE50-455E-4FD0-87A7-354C08D8EDFBQ43980775-EC376767-CC4D-40CB-8ED6-277C73C5AD48Q44400166-64052916-433A-4583-AA5C-942F4EB0E4BAQ44803959-DF64B3A3-6688-4C2C-BEAF-93FE0D1841A1Q44993029-52ED9CAC-9837-473B-BA26-5045C831C13CQ45281330-68A3D8F9-10E1-4E51-A369-0ED2F7260F5DQ45423159-248D3A02-BFBE-4394-9CF4-5AD80CF9F7F3Q46937866-CBBD4944-D23B-4695-9A5E-02515AFBF2CAQ47233623-F7C5206F-1BA1-465C-B316-6BEB9537DE42Q49073742-7BB62476-78AB-47AE-8C9C-2E4ED389F9BEQ49124920-72230F1E-E9A9-49C7-BFF4-4B3DA80BA846Q50792370-63C51D8A-852E-469C-9450-FF3FBA073D46Q51826784-2F33A4DF-09A2-4D7A-B66C-1CAC0078F915Q51833962-0E63696D-38B1-420C-B791-7CAB9BD30B6CQ52137047-009A4DB5-70C9-4989-8BCB-CC4B22E8CD70Q52941167-53C17B8B-3C46-42AD-9CFF-D51E066FC6D6
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Giordano
@ast
Nicola Giordano
@en
Nicola Giordano
@es
Nicola Giordano
@nl
Nicola Giordano
@sl
type
label
Nicola Giordano
@ast
Nicola Giordano
@en
Nicola Giordano
@es
Nicola Giordano
@nl
Nicola Giordano
@sl
prefLabel
Nicola Giordano
@ast
Nicola Giordano
@en
Nicola Giordano
@es
Nicola Giordano
@nl
Nicola Giordano
@sl
P214
P106
P21
P214
P31
P496
0000-0001-5423-437X